

**Conflict of Interest EMAS Board Members**

Conflicts of interest (COI) arise where there is a divergence between an individual's responsibilities to the EMAS Board and their other interests, such that an individual's motives might be compromised, or perceived to be compromised.

COI include, but are not limited to, the following. Board members are required to disclose any of the following:

1. All relevant financial relationships with commercial interests (entities producing, marketing, re-selling, or distributing goods or services) in any amount as well as the nature of the relationship (personal or immediate family) within the past 5 years e.g.

|                                  |   |  |  |
|----------------------------------|---|--|--|
| Grant/research support           | = | NO   | } no financial link with the pharmaceutical companies        |
| Consultancies                    |   | NO   |  |
| Membership of speakers' bureaux  |   | NO   |  |
| Patent ownership                 |   | NO   |  |
| Membership of board of directors |   | NO   |  |
| Stock shareholding               |   | NO   |  |
| Other financial support          | → | occasional paid work: menopausal slide - Daprona - for NSD | except <del>the</del> meetings in 2015 for TEVA 2016 for NSD |

2. Any non-financial relationships/affiliations relevant to EMAS

I have no potential conflict of interest to report

I have the following potential conflict(s) of interest to report

- Paid Presentation for Symposia: Bayer Healthcare, PRIZER, Effik, IPRAD, GSK, Sanofi-Pasteur, SEREVS Pharma.
- Invitation to International Congresses, Travel and Accommodation expenses paid by Bayer Healthcare, Effik.

Name: Professor Patricia LINES

Signature: 

Date: 29/1/2018